SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-24-001626
Filing Date
2024-02-14
Accepted
2024-02-14 09:51:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 ACRIVON THERAPEUTICS, INC. p24-0648sc13ga.htm SC 13G/A 50183
  Complete submission text file 0000902664-24-001626.txt   52019
Mailing Address C/O MARSHALL WACE NORTH AMERICA L.P. 350 PARK AVE., 18TH FLOOR NEW YORK NY 10022
Business Address C/O MARSHALL WACE NORTH AMERICA L.P. 350 PARK AVE., 18TH FLOOR NEW YORK NY 10022 212-235-2800
Marshall Wace North America L.P. (Filed by) CIK: 0001325091 (see all company filings)

IRS No.: 470943020 | State of Incorp.: DE | Fiscal Year End: 0930
Type: SC 13G/A

Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Subject) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-93824 | Film No.: 24633314
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)